Jolkinolide B synergistically potentiates the antitumor activity of GPX4 inhibitors via inhibiting TrxR1 in cisplatin-resistant bladder cancer cells

Glutathione Peroxidase 4 (GPX4) is a promising Anticancer therapeutic target; however, the application of GPX4 inhibitors (GPX4i) is limited owing to intrinsic or acquired drug resistance. Hence, understanding the mechanisms underlying drug resistance and discovering molecules that can overcome drug resistance are crucial. Herein, we demonstrated that GPX4i killed bladder Cancer cells by inducing lipid reactive oxygen species-mediated Ferroptosis and Apoptosis, and cisplatin-resistant bladder Cancer cells were also resistant to GPX4i, representing a higher half-maximal inhibitory concentration value than that of parent bladder Cancer cells. In addition, thioredoxin reductase 1 (TrxR1) overexpression was responsible for GPX4i resistance in cisplatin-resistant bladder Cancer cells, and inhibiting TrxR1 restored the sensitivity of these cells to GPX4i. In vitro and in vivo studies revealed that Jolkinolide B (JB), a natural diterpenoid and previously identified as a TrxR1 inhibitor, potentiated the antiproliferative efficacy of GPX4i (RSL3 and ML162) against cisplatin-resistant bladder Cancer cells. Furthermore, GPX4 knockdown and inhibition could augment JB-induced Paraptosis and Apoptosis. Our results suggest that inhibiting TrxR1 can effectively improve GPX4 inhibition-based Anticancer therapy. A combination of JB and GPX4i, which is well-tolerated and has several Anticancer mechanisms, may serve as a promising therapy for treating bladder Cancer.

Drug resistance; Jolkinolide B; Lipid peroxidation; Natural diterpenoid; Thioredoxin reductase 1.